Factor VIII therapy for hemophilia A: current and future issues

Louis M. Aledort(Icahn School of Medicine at Mount Sinai), Steven W. Pipe(University of Michigan), Kenneth G. Mann(Haematologic Technologies (United States)), Rolf Ljung(Lund University)
Expert Review of Hematology
April 10, 2014
10.1586/17474086.2014.899896
Cited by 26

Related Papers

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis.
|PubMed|2001|803
Definitions in Hemophilia
|Thrombosis and Haemostasis|2001|772
A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs
|Journal of Internal Medicine|1994|613
A More Uniform Measurement of Factor VIII Inhibitors
|Thrombosis and Haemostasis|1975|587